168 related articles for article (PubMed ID: 17074479)
21. Position 5.46 of the serotonin 5-HT2A receptor contributes to a species-dependent variation for the 5-HT2C agonist (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one: impact on selectivity and toxicological evaluation.
Miller KJ; Wu GY; Varnes JG; Levesque P; Li J; Li D; Robl JA; Rossi KA; Wacker DA
Mol Pharmacol; 2009 Dec; 76(6):1211-9. PubMed ID: 19767451
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor agonists.
Shimada I; Maeno K; Kazuta K; Kubota H; Kimizuka T; Kimura Y; Hatanaka K; Naitou Y; Wanibuchi F; Sakamoto S; Tsukamoto S
Bioorg Med Chem; 2008 Feb; 16(4):1966-82. PubMed ID: 18035544
[TBL] [Abstract][Full Text] [Related]
23. Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.
Wacker DA; Varnes JG; Malmstrom SE; Cao X; Hung CP; Ung T; Wu G; Zhang G; Zuvich E; Thomas MA; Keim WJ; Cullen MJ; Rohrbach KW; Qu Q; Narayanan R; Rossi K; Janovitz E; Lehman-McKeeman L; Malley MF; Devenny J; Pelleymounter MA; Miller KJ; Robl JA
J Med Chem; 2007 Mar; 50(6):1365-79. PubMed ID: 17315987
[TBL] [Abstract][Full Text] [Related]
24. Bicyclic heteroarylpiperazines as selective brain penetrant 5-HT6 receptor antagonists.
Ahmed M; Briggs MA; Bromidge SM; Buck T; Campbell L; Deeks NJ; Garner A; Gordon L; Hamprecht DW; Holland V; Johnson CN; Medhurst AD; Mitchell DJ; Moss SF; Powles J; Seal JT; Stean TO; Stemp G; Thompson M; Trail B; Upton N; Winborn K; Witty DR
Bioorg Med Chem Lett; 2005 Nov; 15(21):4867-71. PubMed ID: 16143522
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and in vitro pharmacological evaluation of a new series of 5-HT1A 5-HT2A and 5-HT2C receptor ligands containing a norbornene nucleus.
Fiorino F; Severino B; De Angelis F; Perissutti E; Magli E; Frecentese F; Esposito A; Massarelli P; Nencini C; Viti B; Santagada V; Caliendo G
Pharmazie; 2009 Sep; 64(9):555-64. PubMed ID: 19827295
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and biological evaluation of piperazinyl heterocyclic antagonists of the gonadotropin releasing hormone (GnRH) receptor.
Vera MD; Lundquist JT; Chengalvala MV; Cottom JE; Feingold IB; Garrick LM; Green DM; Hauze DB; Mann CW; Mehlmann JF; Rogers JF; Shanno L; Wrobel JE; Pelletier JC
Bioorg Med Chem Lett; 2010 Apr; 20(8):2512-5. PubMed ID: 20236823
[TBL] [Abstract][Full Text] [Related]
27. Optimization of the pharmacophore model for 5-HT7R antagonism. Design and synthesis of new naphtholactam and naphthosultam derivatives.
López-Rodríguez ML; Porras E; Morcillo MJ; Benhamú B; Soto LJ; Lavandera JL; Ramos JA; Olivella M; Campillo M; Pardo L
J Med Chem; 2003 Dec; 46(26):5638-50. PubMed ID: 14667218
[TBL] [Abstract][Full Text] [Related]
28. 3-(4-Piperidinyl)- and 3-(8-aza-bicyclo[3.2.1]oct-3-yl)-2-phenyl-1H-indoles as bioavailable h5-HT2A antagonists.
Crawforth J; Goodacre S; Maxey R; Bourrain S; Patel S; Marwood R; O'Connor D; Herbert R; Hutson P; Rowley M
Bioorg Med Chem Lett; 2000 Dec; 10(24):2701-3. PubMed ID: 11133072
[TBL] [Abstract][Full Text] [Related]
29. The design and synthesis of a tricyclic single-nitrogen scaffold that serves as a 5-HT2C receptor agonist.
Huck BR; Llamas L; Robarge MJ; Dent TC; Song J; Hodnick WF; Crumrine C; Stricker-Krongrad A; Harrington J; Brunden KR; Bennani YL
Bioorg Med Chem Lett; 2006 Aug; 16(15):4130-4. PubMed ID: 16750364
[TBL] [Abstract][Full Text] [Related]
30. Design and synthesis of indole-based peptoids as potent noncompetitive antagonists of transient receptor potential vanilloid 1.
Quintanar-Audelo M; Fernández-Carvajal A; Van Den Nest W; Carreño C; Ferrer-Montiel A; Albericio F
J Med Chem; 2007 Nov; 50(24):6133-43. PubMed ID: 17985859
[TBL] [Abstract][Full Text] [Related]
31. 2-Alkyl-4-aryl-pyrimidine fused heterocycles as selective 5-HT2A antagonists.
Shireman BT; Dvorak CA; Rudolph DA; Bonaventure P; Nepomuceno D; Dvorak L; Miller KL; Lovenberg TW; Carruthers NI
Bioorg Med Chem Lett; 2008 Mar; 18(6):2103-8. PubMed ID: 18282705
[TBL] [Abstract][Full Text] [Related]
32. Identification of novel short chain 4-substituted indoles as potent alphavbeta3 antagonist using structure-based drug design.
Raboisson P; Desjarlais RL; Reed R; Lattanze J; Chaikin M; Manthey CL; Tomczuk BE; Marugán JJ
Eur J Med Chem; 2007 Mar; 42(3):334-43. PubMed ID: 17184884
[TBL] [Abstract][Full Text] [Related]
33. A series of bisaryl imidazolidin-2-ones has shown to be selective and orally active 5-HT2C receptor antagonists.
Goodacre CJ; Bromidge SM; Clapham D; King FD; Lovell PJ; Allen M; Campbell LP; Holland V; Riley GJ; Starr KR; Trail BK; Wood MD
Bioorg Med Chem Lett; 2005 Nov; 15(22):4989-93. PubMed ID: 16168649
[TBL] [Abstract][Full Text] [Related]
34. Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization.
Elokdah H; Abou-Gharbia M; Hennan JK; McFarlane G; Mugford CP; Krishnamurthy G; Crandall DL
J Med Chem; 2004 Jul; 47(14):3491-4. PubMed ID: 15214776
[TBL] [Abstract][Full Text] [Related]
35. Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists.
Cheng Y; Albrecht BK; Brown J; Buchanan JL; Buckner WH; DiMauro EF; Emkey R; Fremeau RT; Harmange JC; Hoffman BJ; Huang L; Huang M; Lee JH; Lin FF; Martin MW; Nguyen HQ; Patel VF; Tomlinson SA; White RD; Xia X; Hitchcock SA
J Med Chem; 2008 Aug; 51(16):5019-34. PubMed ID: 18680277
[TBL] [Abstract][Full Text] [Related]
36. Synthesis of new serotonin 5-HT7 receptor ligands. Determinants of 5-HT7/5-HT1A receptor selectivity.
Medina RA; Sallander J; Benhamú B; Porras E; Campillo M; Pardo L; López-Rodríguez ML
J Med Chem; 2009 Apr; 52(8):2384-92. PubMed ID: 19326916
[TBL] [Abstract][Full Text] [Related]
37. Synthesis of 2,5-thiazole butanoic acids as potent and selective alpha(v)beta3 integrin receptor antagonists with improved oral pharmacokinetic properties.
Wendt JA; Wu H; Stenmark HG; Boys ML; Downs VL; Penning TD; Chen BB; Wang Y; Duffin T; Finn MB; Keene JL; Engleman VW; Freeman SK; Hanneke ML; Shannon KE; Nickols MA; Steininger CN; Westlin M; Klover JA; Westlin W; Nickols GA; Russell MA
Bioorg Med Chem Lett; 2006 Feb; 16(4):845-9. PubMed ID: 16303301
[TBL] [Abstract][Full Text] [Related]
38. Discovery of a novel indole series of EP1 receptor antagonists by scaffold hopping.
Hall A; Billinton A; Brown SH; Chowdhury A; Giblin GM; Goldsmith P; Hurst DN; Naylor A; Patel S; Scoccitti T; Theobald PJ
Bioorg Med Chem Lett; 2008 Apr; 18(8):2684-90. PubMed ID: 18378447
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.
Ivachtchenko AV; Frolov EB; Mitkin OD; Kysil VM; Khvat AV; Okun IM; Tkachenko SE
Bioorg Med Chem Lett; 2009 Jun; 19(12):3183-7. PubMed ID: 19443217
[TBL] [Abstract][Full Text] [Related]
40. Novel fibrinogen receptor antagonists. RGDF mimetics, derivatives of 4-(isoindoline-5-yl)amino-4-oxobutyric acid.
Krysko AA; Chugunov BM; Malovichko OL; Andronati SA; Kabanova TA; Karaseva TL; Kiriyak AV
Bioorg Med Chem Lett; 2004 Nov; 14(22):5533-5. PubMed ID: 15482918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
